Third Dose of Pfizer/BioNTech Covid-19 vaccine 95.6% Effective: Study


A third dose of the vaccine against Covid-19 developed by Pfizer/BioNTech is 95.6 per cent effective against symptomatic infection, according to a study by the makers published on Thursday.

The clinical phase three trial with “10,000 participants 16 years of age and older” showed “a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain”, the companies said in a statement.

Read all the Latest News, Breaking News and Coronavirus News here. Follow us on Facebook, Twitter and Telegram.





Source link

Author: Shirley

Leave a Reply

Your email address will not be published. Required fields are marked *